The University of Southampton
University of Southampton Institutional Repository

Combination therapy with acipimox enhances the effect of growth hormone treatment on linear body growth in the normal and small-for-gestational-age rat

Vickers, M.H., Hofman, P.L., Gluckman, P.D., Lobie, P.E. and Cutfield, W.S. (2006) Combination therapy with acipimox enhances the effect of growth hormone treatment on linear body growth in the normal and small-for-gestational-age rat American Journal of Physiology: Endocrinology and Metabolism, 291, (6), E1212-E1219. (doi:10.1152/ajpendo.00614.2005).

Record type: Article


Growth hormone (GH) therapy is often associated with adverse side effects, including impaired insulin sensitivity. GH treatment of children with idiopathic short stature does not lead to an optimized final adult height. It has been demonstrated that FFA reduction induced by pharmacological antilipolysis can stimulate GH secretion per se in both normal subjects and those with GH deficiency. However, to date, no investigation has been undertaken to establish efficacy of combination treatment with GH and FFA regulators on linear body growth. Using a model of maternal undernutrition in the rat to induce growth-restricted offspring, we investigated the hypothesis that combination treatment with GH and FFA regulators can enhance linear body growth above that of GH alone. At postnatal day 28, male offspring of normally nourished mothers (controls) and offspring born with low birth weight [small for gestational age (SGA)] were treated with saline, GH, or GH (5 in combination with acipimox (GH + acipimox, 20 or fenofibrate (GH + fenofibrate, 30 for 40 days. GH plus acipimox treatment significantly enhanced linear body growth in the control and SGA animals above that of GH, as quantified by tibial and total body length. Treatment with GH significantly increased fasting plasma insulin, insulin-to-glucose ratio, and plasma volumes in control and SGA animals but was not significantly different between saline and GH-plus-acipimox-treated animals. GH-induced lipolysis was blocked by GH plus acipimox treatment in both control and SGA animals, concomitant with a significant reduction in fasting plasma FFA and insulin concentrations. This is the first study to show that GH plus acipimox combination therapy, via pharmacological blocking of lipolysis during GH exposure, can significantly enhance the efficacy of GH in linear growth promotion and ameliorate unwanted metabolic side effects

Full text not available from this repository.

More information

Published date: December 2006
Keywords: growth hormone, acipimox, insulin, free fatty acids


Local EPrints ID: 61584
ISSN: 0193-1849
PURE UUID: 51cc56a7-a92b-4685-aed2-ccd089061778

Catalogue record

Date deposited: 10 Sep 2008
Last modified: 17 Jul 2017 14:21

Export record



Author: M.H. Vickers
Author: P.L. Hofman
Author: P.D. Gluckman
Author: P.E. Lobie
Author: W.S. Cutfield

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton:

ePrints Soton supports OAI 2.0 with a base URL of

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.